)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Terumo
Terumo (4543) investor relations material
Terumo Q2 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2027 earnings summary12 Nov, 2026
Executive summary
H1 revenue reached a record ¥624.5B, up 16.7% reported and 8.0% excluding FX; adjusted operating profit rose 28.8% to a record ¥147.3B.
Reported operating profit fell 29.9% to ¥70.8B and net profit fell 29.0% to ¥54.6B, mainly due to impairment and related costs following the CSL Plasma supply-agreement termination.
Financial highlights
H1 gross profit rose 18.0% to ¥345.0B; gross margin increased to 55.2% from 54.7%.
Adjusted operating margin increased to 23.6% from 21.4%; reported operating margin declined to 11.3% from 18.9%.
Profit before tax was ¥69.5B; diluted EPS was ¥37.02 versus ¥52.12 a year earlier.
H1 free cash flow was ¥122.6B, up ¥91.6B YoY.
Outlook and guidance
Full-year revenue guidance is ¥1,219.5B (+7.7% YoY); adjusted operating profit is ¥271.5B (+23.8%), with a 22.3% margin.
Operating profit guidance was reduced to ¥119.0B (-32.5% YoY) and parent-attributable profit to ¥87.5B (-35.6% YoY).
Revised guidance reflects the Aortic recall, related asset-value risks and temporary Neuro supply constraints; assumptions include ¥155/$ and ¥180/€.
Organ Technologies retained its 20% full-year profit margin target, with second-half growth expected from sales expansion.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Terumo
- Integrated manufacturing and AI accelerate differentiated product innovation and sustainable growth.4543
Status update - CSL Plasma exit drives US$610M in estimated FY26 charges; TBCT profitability expected to improve from FY27.4543Investor presentation
- Acquisition adds next-gen liquid embolic for cSDH, expanding neurovascular market reach.4543Acquisition presentation
- Record-high revenue and profit on global demand, FX gains, and one-time items; guidance raised.4543Q1 2027
- FY26 targets robust growth through innovation, new devices, and expansion in Africa and organ technologies.4543Investor Day 2026
- Record revenue and profit, with double-digit growth expected to continue in FY2026/2027.4543Q4 2026
- Record revenue and profit growth driven by global demand and strategic acquisitions.4543Q3 2026
- Record revenue and profit growth, with double-digit gains and improved margins.4543Q1 2025
- Record revenue and profit growth, with global expansion and CDMO investment; tariff risks persist.4543Q4 2025
Next Terumo earnings date
Q3 202712 Feb, 2027
Terumo
Next Terumo earnings date
Q3 202712 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Terumo Corporation develops, manufactures, and distributes medical devices and services. The company's products include airway management devices such as catheters, cannulas, balloons and valves; minimally invasive surgery systems; infusion systems; cartridges for dialysis machines; intrauterine systems for contraception; endoscopic systems for gastrointestinal endoscopy and bronchoscopy procedures; surgical lasers for eye surgery; films for X-rays or pictures of body organs; imaging apparatus for magnetic resonance images (MRIs) and computed tomography (CT) scans; home transfusion treatment machines; products used in blood conservation therapy such as apheresis machines used to separate blood components such as plasma or platelets from whole blood using centrifugal force. The company is based in Tokyo, Japan.